NCT04079712: Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have only one line of prior systemic cancer treatment
Exclusions: Patients with leptomeningeal metastases or known, untreated, symptomatic brain metastases requiring steroids – see trial for details; Patients with prior treatment of XL184/cabozantinib, MET-targeting tyrosine kinase inhibitor or monoclonal antibody (e.g.onartuzumaban), anti-PD-1/PD-L1/2 or anti-CTLA-4 antibody, or any other drug specifically targeting T cell co-stimulation or immune checkpoint pathways

Comments are closed.

Up ↑